ProKidney Corp
ProKidney Corp. is a U.S.-based clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease. Its business centers on rilparencel, an autologous renal cell therapy designed to preserve kidney function, along with related manufacturing and clinical development activities in the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutologous cell-based therapies under clinical development for kidney disease.
Research, trial execution, regulatory work, and development activities for rilparencel.
Manufacturing infrastructure and related operational activities supporting the therapy platform.
Revenue from leasing activities associated with buildings used in operations.
Customers
ProKidney does not yet sell a commercial product, so its direct end customers are not established in the traditional sense. Its future customer base is expected to include patients with type 2 diabetes and advanced chronic kidney disease, accessed through physicians, nephrology centers, and healthcare systems if rilparencel is approved. The company also may pursue collaboration or license partners that could pay for development or commercialization rights.
Patients with type 2 diabetes and advanced chronic kidney disease who would receive rilparencel if approved.
Physicians and specialty care centers that would identify, refer, and administer therapy pathways.
Potential collaborators or licensees that could fund development or commercialization.
Counterparties to the company’s lease arrangements tied to its manufacturing-related buildings.
Strategy
ProKidney’s strategy is to advance rilparencel through late-stage clinical development and secure regulatory approval in the United States. It also seeks to maintain manufacturing readiness and preserve optionality through collaborations, licensing, or other strategic transactions while funding development through external capital sources.
Approval depends on demonstrating safety and efficacy in advanced CKD patients.
Commercial value depends on FDA review and acceptance of the clinical package.
A cell therapy requires controlled production, logistics, and quality systems before launch.
Development-stage biotech requires ongoing external funding before product revenue exists.
Geography
ProKidney is headquartered in the United States and conducts its manufacturing operations in Winston-Salem, North Carolina. Its development program is centered on the U.S. market, where it is pursuing regulatory approval for rilparencel. The company also has an international corporate history, but its operating footprint is now primarily U.S.-based.
Risks
ProKidney faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the possibility that its product candidate never reaches commercialization. It also depends on external financing and on maintaining manufacturing and quality systems that meet FDA expectations, while its lease-related revenue is limited and not representative of a commercial operating base.
- Clinical development failure for rilparencelImpact: Critical
The company’s value depends on positive trial data and eventual approval.
Exposure: PROACT 1 and REGEN-007
- FDA and regulatory uncertaintyImpact: HighLikelihood: High
Approval timing and requirements can change, affecting launch prospects.
Exposure: U.S. regulatory pathway
- Financing and dilution riskImpact: High
The company expects to fund operations through external capital sources.
Exposure - Manufacturing and quality complianceImpact: High
Cell therapy production requires strict controls and regulatory compliance.
Exposure: Winston-Salem manufacturing operations
- Government and trade policy disruptionImpact: MediumLikelihood: High
Changes in tariffs or agency operations can affect supply chains and oversight.
Exposure: U.S. regulatory and import/export environment
Accounting
Judgemental itemsRevenue now includes lease-related income from acquired buildings, which is separate from product revenue.
Impact: Affects reported revenue and asset utilization
Clinical trial, CRO, and regulatory costs require judgment on timing and completeness of accruals.
Impact: Affects operating expense timing
Equity awards and forfeitures can materially affect G&A and R&D expenses.
Impact: Affects non-cash operating expense
Any licensing or partnership payments would require careful revenue recognition analysis.
Impact: Could change revenue profile materially
Similar listed companies
Publicly listed companies with a comparable business focus.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026